Novartis hops on KRAS craze with early data, seeking to improve on undruggable target BioNTech showcases post-Comirnaty future with early cancer vaccine efficacy data Bristol Myers details Opdivo's presurgery lung cancer win, with an early sign of survival benefit 2 years in, Amgen fortifies Lumakras lung cancer data fortress for upcoming Mirati, Novartis KRAS battle Senti Bio fine-tunes cytokines to boost CAR-NK cell therapy for solid cancers Exuma aims to be first to the clinic with under-the-skin cancer CAR cell therapy without complex manufacturing Novartis aims to keep canakinumab's early lung cancer hopes alive despite metastatic failure C4's multiple myeloma data prompt dosing switch, giving patients a longer treatment reprieve Blueprint wants to make resistance to AstraZeneca's Tagrisso futile in lung cancer AbbVie's navitoclax goes after tough blood cancer, not yet reaching overall survival benchmark Featured Story | By Annalee Armstrong, Angus Liu Finding a way to drug KRAS-mutated cancers was a major leap forward for oncology, and we have Amgen to thank for getting the first therapy across the finish line. But Novartis, for one, sees room for improvement. read more |
| |
|---|
|
Top Stories By Annalee Armstrong BioNTech’s post-Comirnaty future is emerging, with early phase 1/2 data from a solid tumor CAR-T cell therapy showing evidence of efficacy and a safety profile deemed manageable by the famed German biotech. read more By Angus Liu Bristol Myers Squibb presented details on what triggered a quick FDA nod in March for Opdivo in early-stage non-small cell lung cancer before surgery, including a disease worsening benefit across patient groups and an early sign of life extension. read more By Angus Liu Amgen is busy building Lumakras’ case, taking advantage of an unexpectedly longer lead over KRAS rival Mirati Therapeutics. Two years in, Lumakras’ data in previously treated KRAS G12C-mutated non-small cell lung cancer continued to look solid. read more By Angus Liu Senti Bio is perhaps best known for logic-gated gene circuits to control the therapeutic activity of cell and gene therapies. But CEO Tim Lu, M.D., Ph.D., has early data showing the biotech's CAR-NK platform has more tricks up its sleeve. read more By Angus Liu Existing CAR-T therapies for blood cancers require painstaking preparation. Exuma Biotech believes its rapidly manufactured cell therapy can save patients precious time and obviate the need for preconditioning. read more By Angus Liu When Novartis failed in an attempt to repurpose Ilaris for metastatic non-small cell lung cancer, the Swiss pharma played up signs that it said supported continued exploration of the med in earlier stages of disease. Now, the company has unveiled those data. read more By Annalee Armstrong C4 Therapeutics has learned a lot from just five melanoma patients reporting out from the first cohort in a phase 1 trial for its lead candidate, a IKZF1/3 degrader called CFT7455. In data to be presented at the AACR meeting in New Orleans on April 12, C4 will showcase the early efficacy signals. read more By Annalee Armstrong About seven out of 10 patients with EGFR-mutated lung cancer progress after taking AstraZeneca’s Tagrisso, and a third of those patients see their cancer spread to the brain. Blueprint wants to change that. read more By Annalee Armstrong Myelofibrosis is the cancer that keeps going and going—and AbbVie hopes new data from the phase 2 med navitoclax can make the case for stopping the rare and difficult-to-treat disease in its tracks. read more |
